Preferences help
enabled [disable] Abstract
Number of results
2008 | 3 | 1 | 29-39
Article title

DCC and TS protein expression in resected gastric cancer: A Hellenic Cooperative Oncology Group Study

Title variants
Languages of publication
There is a high risk of relapse after resection of gastric cancer. We studied the prognostic significance of the deleted colorectal cancer (DCC) gene and thymidylate synthase (TS) protein expression after resection of gastric cancer. Protein expression in the primary tumor of 146 patients with serosal and/or lymph node involvement was studied immunohistochemically by using anti-DCC and anti-TS monoclonal antibodies. DCC expression was found in 69.9%, while low TS staining intensity (0+,1+) and focal staining (<25% of tumor cells stained) were found in 44.6% and 33.8%, respectively. Overall survival (OS) was significantly longer in patients with DCC (p=0.014) negative tumors. TS expression was not an independent prognostic factor. Lack of DCC expression was associated with significantly longer cause-specific survival (CSS) (p=0.040) after curative resection. In conclusion, DCC expression is an independent prognostic factor in patients undergoing resection of gastric cancer while TS expression was not associated with the prognosis in our study.
DCC   TS   Gastric cancer  
Physical description
1 - 3 - 2008
1 - 3 - 2008
  • Oncology Dept, Ioannina University Hospital, Ioannina, Greece
  • AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Histocytopathology Laboratory, Ioannina University Hospital, Ioannina, Greece
  • AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • Histocytopathology Laboratory for Social Insurance, Thessaloniki, Greece
  • Ippokration Hospital, Athens, Greece
  • Ippokration Hospital, Athens, Greece
  • Oncology Dept, Ioannina University Hospital, Ioannina, Greece
  • Evangelismos Hospital, Athens, Greece
  • Histocytopathology Laboratory, Ioannina University Hospital, Ioannina, Greece
  • [1] Alexander H.R., Kelsen D.P., Tepper J.E., Cancer of the stomach. In: De Vita VT, Hellman S, Rosenberg SA, (Eds.) Cancer. Principles and Practice of Oncology, Philadelphia, Lippincot-Raven Publishers, 1997, 1021–1053
  • [2] Fuchs C.S., Mayer R.J., Gastric carcinoma., N. Engl. J. Med., 1995, 333, 32–41[Crossref]
  • [3] Kelsen D.P., Adjuvant and neoadjuvant therapy for gastric cancer., Semin. Oncol., 1996, 23, 379–389
  • [4] Cho K.R., Fearon E.R., DCC: Linking tumor suppressor genes and altered cell surface interactions in cancer?, Eur. J. Cancer., 1995, 31A, 1055–1060[Crossref]
  • [5] Uchino S., Tsuda H., Noguchi M., Yokota J., Terada M., Saito T., et al., Frequent loss of heterozygosity at the DCC locus in gastric cancer., Cancer. Res., 1992, 52, 3099–3102
  • [6] Fang D.C., Jass J.R., Wang D.X., Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer., J. Clin. Pathol., 1998, 51, 593–596[Crossref]
  • [7] Cropp C.S., Lidereau R., Campbell G., Champene M.H., Callahan R., Loss of heterozygosity on chromosome 17 and 18 in breast carcinoma: two additional regions identified., Proc. Natl. Acad. Sci. USA, 1990, 87, 7737–7741[Crossref]
  • [8] Gao X., Honn K.V., Grignon D., Sakr W., Chen Y.Q., Frequent loss of expression and loss of heterozygosity of putative tumor suppressor gene DCC in prostatic carcinomas., Cancer. Res., 1993, 53, 2723–2727
  • [9] Peng H.Q., Bailey D., Bronson D., Goss P.D., Hong D., Loss of heterozygosity of tumor suppressor genes in testis cancer., Cancer. Res., 1995, 55, 2871–2875
  • [10] Jen J., Kim H., Piantadosi S., Liu Z.F., Levitt R.C., Sistonen P., et al., Allelic loss of chromosome 18q and prognosis in colorectal cancer., N. Engl. J. Med., 1994, 331, 213–221[Crossref]
  • [11] O’Connell M.J, Schaid D.J., Ganju V., Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis?, Cancer., 1992, 70, 1732–1739<1732::AID-CNCR2820701614>3.0.CO;2-#[Crossref]
  • [12] Watanabe T., Tsung-The W., Catalano P.J., Ueki T., Satriano R., Haller D.G., et al., Molecular predictors of survival after adjuvant chemotherapy for colon cancer., N. Engl. J. Med., 2001, 344, 1196–1206[Crossref]
  • [13] Shibata D., Reale M.A., Lavin P., Silverman M., Fearon E.R., Steele G., et al., The DCC protein and prognosis in colorectal cancer., N. Engl. J. Med., 1996, 335, 1727–1732[Crossref]
  • [14] Sun X.F., Rutten S., Zhang H., Nordenskjold B., Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma., J. Clin. Oncol., 1999, 17, 1745–1750
  • [15] Candusso M.E., Luinetti O., Villani L., Alberizzi P., Klersy C., Fiocca R., et al., Loss of heterozygosity at 18q21 region in gastric cancer involves a number of cancer-related genes and correlates with stage and histology, but lacks independent prognostic value., J. Pathol. 2002, 197, 44–50[Crossref]
  • [16] Bamias A.T., Bai M.C., Agnantis N.J., Michael M.C., Alamanos Y.P., Stefanaki S.V., et al., Prognostic significance of the deleted in colorectal cancer (DCC) gene expression in high risk resected gastric carcinoma., Cancer. Investigation, 2003, 21, 333–340[Crossref]
  • [17] Pinedo H.M., Peters G.F.J., Fluorouracil: Biochemistry and pharmacology., J. Clin. Oncol., 1988, 6, 1653–1664
  • [18] Aschele C., Debernardis D., Casazza S., Antonelli G., Tunesi G., Baldo C., et al., Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to Fluorouracil-based chemotherapy., J. Clin. Oncol., 1999, 17, 1760–1770
  • [19] Lenz H.J., Hayashi K., Salonga D., Danenberg K.D., Danenberg P.V., Metzger R., et al., P53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival., Clin. Cancer. Res., 1998, 4, 1243–1250
  • [20] Boku N., Chin K., Hosokawa K., Ohtsu A., Tajiri H., Yoshida S., et al., Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-Fluorouracil and cis-Platinum., Clin. Cancer. Res., 1998, 4, 1469–1474
  • [21] Pestalozzi B.C., Peterson H.F., Gelber R.D., Goldhirsch A., Gusterson B.A., Trihia H., et al., Prognostic importance of thymidylate synthase expression in early breast cancer., J. Clin. Oncol., 1997, 15, 1923–1931
  • [22] Edler D., Kressner U., Ragnhammar P., Johnston P.G., Magnusson I., Glimelius B., et al., Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival., Clin. Cancer. Res., 2000, 6, 488–492
  • [23] Johnston P.G., Fisher E.R., Rockette H.E., Fisher B., Wolmark N., Drake J.C., et al., The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer., J. Clin. Oncol., 1994, 12, 2640–2647
  • [24] Allegra C.J., Parr A.L., Wold L.E., Mahoney M.R., Sargent D.J., Johnston P.G., et al., Investigation of the prognostic and predicitve value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer., J. Clin. Oncol., 2002, 20, 1735–1743[Crossref]
  • [25] Lenz H.J., Leichman C.G., Danenberg K.D., Danenberg P.V., Groshen S., Cohen H., et al., Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival., J. Clin. Oncol., 1996, 14, 1176–1182
  • [26] Suda Y., Kuwashima Y., Tanaka Y., Uchida K., Akazawa S., Immunohistochemical detection of thymidylate synthase in advanced gastric cancer: a prognostic indicator in patients undergoing gastrectomy followed by adjuvant chemotherapy with 5-Fluoropyrimidines., Anticancer. Res., 1999, 19, 805–810
  • [27] Choi J.H., Lim H.Y., Nam D.K., Kim H.S., Cho D.Y., Yi J.W., et al., Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection., Br. J. Cancer., 2001, 84, 186–192[Crossref]
  • [28] Kuniyashu T., Nakamura T., Tabuchi Y., Kuroda Y., Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody., Cancer., 1998, 83, 1300–1306<1300::AID-CNCR5>3.0.CO;2-M[Crossref]
  • [29] Ishikawa Y., Tetsuro K., Otani Y., Watanabe M., Teramoto T., Kumai K., et al., Thymidylate synthetase and Dihydropyrimidine dehydrogenase levels in gastric cancer., Anticancer. Res., 1999, 19, 5635–5640
  • [30] Pestalozzi B.C., McGinn C.J., Kinsella T.J., Increased thymidylate synthase protein levels are associated with proliferation but not cell cycle phase in asynchronous human cancer cells., Br. J. Cancer., 1995, 71, 1151–1157 [Crossref]
  • [31] Yonemura Y., Kimura H., Fushida S., Tugawa K., Nakai Y., Kaji M., et al., Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy., Cancer. 1993, 71, 2448–2453<2448::AID-CNCR2820710804>3.0.CO;2-V[Crossref]
  • [32] Kakeji Y., Maehara Y., Adachi Y., Baba H., Mori M., Furusawa M., et al., Proliferative activity as a prognostic factor in Bormann type 4 gastric carcinoma., Br. J. Cancer., 1994, 69, 749–753 [Crossref]
  • [33] Bai M., Vlachoniklis J., Agnantis N.J., Tsanou E., Dimou S., Nicolaides C., et al., Low expression of p27 protein combined with altered p53 and Rb/p16 status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas., Mod. Pathol. 2001, 14(11), 1105–1113
  • [34] Armitage P., Berry G., Statistical methods in medical research. Oxford, United Kingdom, Blackwell Scientific Publications, 1994
  • [35] Kaplan E., Meier P., Nonparametric estimation from incomplete observations., J. Am. Stat. Assoc., 1958, 53, 457–481[Crossref]
  • [36] Cox D.R., Regression models and life tables., J. R. Stat. Soc. B., 1972, 34, 187–220
  • [37] MacDonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., et al., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction., N. Engl. J. Med., 2001, 345, 725–730[Crossref]
  • [38] Sato K., Tamura G., Tsuchiya T., Endoh Y., Usuba O., Kimura W., et al., Frequent loss of expression without sequence mutations of the gene in primary gastric cancer., Br. J. Cancer., 2001, 85(2), 199–203[Crossref]
  • [39] Johnston P.J., Lenz H.J., Leichman C.G., Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors., Cancer. Res., 1995, 55, 1407–1412
  • [40] Edler D., Glimelius B., Hallstrom M., Jacobsen A., Johnston P.G., Magnuson I., et al., Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy., J. Clin. Oncol., 2002, 20, 1721–1728[Crossref]
  • [41] Schipper D.L., Wagenmans M.J.M., Peters W.H.M., Wagener D.J.T., Significance of cell proliferation measurement in gastric cancer., Eur. J. Cancer., 1998, 34, 781–790[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.